Collectively, the available data suggested that epigenetic agents may prime the tumor microenvironment for immune checkpoint inhibition by triggering an IFN response, and that concurrent blockade of IFN-regulated resistance pathways via IDO1 could provide further clinical benefit. Here, IDO1 is linked to neoplasm.